A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 3
- 主要终点
- Number of participants with adverse events and serious adverse events
研究概览
简要总结
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors.
详细描述
This trial will have a run-in phase to explore the safety and tolerability of YH001 as a single agent for 21 days as DLT observation period then followed by a combination phase to further explore the safety and tolerability of YH001 combined with Toripalimab (anti-PD-1 antibody) for each dose level during dose escalation.
The dose escalation will follow the traditional "3 + 3" dose escalation scheme. These subjects will be treated with YH001 and Toripalimab. YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G. Toripalimab will be administered by IV (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle. A single subject will be enrolled at Dose A as starting dose of YH001, and subsequent cohort will be expanded to include 3-6 subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged ≥ 18 years
- •Have advanced histologically or cytologically confirmed solid tumor
- •Have progressed on after treatment with standard therapies or intolerant of standard care
- •At least 1 unidimensional measurable target lesion per RECIST v1.1
- •Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- •Have life expectancy of at least 12 weeks based on investigator's judgement
排除标准
- •Treated with any investigational drug within 4 weeks prior to the fist dose of study drug
- •Received any anticancer therapy less than 28 days prior to the first administration of study drug or within 5 half-lives of the therapy agent, whichever is shorter. Prior palliative radiotherapy to bone metastases ≤ 2 weeks prior to the first dose of YH001 is acceptable
- •Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded
- •Subjects with prior PD-1/L1 treatment intolerate to PD-1/L1 therapy should be excluded
- •Subjects with a history of ≥ Grade 3 immune-related adverse events (AEs) resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy
- •Subjects with a history of ≥ Grade 2 pneumonitis resulted from previous immunotherapy or with a SpO2 by pulse oximetry < 92% at the screening
- •Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Ophthalmologic, nasal and intra-articular injections of steroids are allowed
- •Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry. Exceptions are subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by replacement therapy
- •Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. But subjects with asymptomatic CNS metastases might be eligible if they have no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and the first dose of YH001 and are currently not receiving corticosteroids
- •QTc > 450 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome
- •Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ Grade 1 per CTCAE v5.0, except alopecia, < Grade 2 sensory neuropathy
研究组 & 干预措施
YH001 combined with Toripalimab
All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
干预措施: YH001 (Drug)
YH001 combined with Toripalimab
All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
干预措施: Toripalimab (Drug)
结局指标
主要结局
Number of participants with adverse events and serious adverse events
时间窗: From screening up to 1 year
The safety profile of YH001 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Maximum tolerated dose (MTD)
时间窗: During Cycle 1 (each cycle is 21 days)
MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle
Dose-limiting toxicities (DLT)
时间窗: During Cycle 1 (each cycle is 21 days)
DLT is defined as a toxicity (adverse event at least possibly related to YH001) occurring during the DLT observation period (the initial 21 days) both in run-in phase of YH001 as single agent and in combination phase of YH001 in combination with Toripalimab
次要结局
- Maximum serum concentration (Cmax)(Up to 1 year)
- Trough concentration before the next dose is administered (Ctrough)(Up to 1 year)
- Time to reach maximum serum concentration (Tmax)(Up to 1 year)
- Terminal half-life (T1/2)(Up to 1 year)
- Incidence of anti-drug antibodies (ADAs)(Up to 1 year)
- Objective response rate (ORR)(Up to 1 year)
- Overall survival (OS)(Up to 1 year)
- Disease control rate (DCR)(Up to 1 year)
- Duration of disease control (DDC)(Up to 1 year)
- Area under the serum concentration versus time curve within one dosing interval (AUCtau)(Up to 1 year)
- Steady state AUC(Up to 1 year)
- Clearance (CL)(Up to 1 year)
- Dose proportionality(Up to 1 year)
- Incidence of neutralizing antibodies (NAbs)(Up to 1 year)
- Duration of response (DOR)(Up to 1 year)
- Time to response (TTR)(Up to 1 year)
- Progression free survival (PFS)(Up to 1 year)
- Volume of distribution (Vd)(Up to 1 year)